This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: University of Washington. Active years: 2010-2018.
Company Filing History:
Years Active: 2010-2018
Title: Zoran Brkanac: Innovator in Ataxic Neurological Disease Research
Introduction
Zoran Brkanac is a prominent inventor based in Seattle, WA (US), known for his significant contributions to the field of genetics and neurological diseases. He holds 2 patents that focus on identifying genetic mutations associated with ataxic neurological diseases. His work has the potential to greatly impact the understanding and treatment of these conditions.
Latest Patents
Brkanac's latest patents include innovative methods and kits for identifying subjects susceptible to ataxic neurological disease. One of his inventions provides methods for identifying genetic mutations linked to ataxic neurological disease by comparing nucleic acid sequences of the protein kinase C gamma gene from affected and unaffected subjects. Additionally, he has developed isolated nucleic acid molecules encoding protein kinase C gamma missense mutations. His inventions also encompass methods for screening subjects to determine their genetic predisposition to develop ataxic neurological disease, along with kits designed to assess susceptibility or presence of the disease in mammalian subjects.
Career Highlights
Zoran Brkanac is affiliated with the University of Washington, where he conducts his research and development work. His academic background and ongoing research contribute to the advancement of genetic studies and neurological health.
Collaborations
Brkanac collaborates with esteemed colleagues such as Wendy H Raskind and Dong-Hui Chen, enhancing the depth and breadth of his research efforts.
Conclusion
Zoran Brkanac's innovative work in identifying genetic mutations related to ataxic neurological diseases positions him as a key figure in the field of genetics. His contributions are paving the way for improved diagnostic methods and potential treatments for affected individuals.
